Oral · GLP-1 agonist
TQF3250
3 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
3
Ongoing
3
Recruiting
3
Completed
0
Sites
17
Countries
1
Endpoints
69
Composite endpoints
1
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
3
Trials by status
Recruiting
3
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
32
Other (unclassified)
16
Glycemic / diabetes
9
Weight & body composition
7
Cardiometabolic biomarkers
4
Other clinical outcomes
1
Top 20 metrics across this asset's endpoints
AUC₀-∞Safety/PK
3
CmaxSafety/PK
2
Treatment-emergent AEs (any)Safety/PK
1
Heart rate, changeBiomarker
1
TmaxSafety/PK
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
3 of 3
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT07747857A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity | TQF3250 Obesity / overweight, Type 2 diabetes | - | Ph 1 | Recruiting | 12 | Jun 2027 | - | |
| NCT07798284A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention | TQF3250 Obesity / overweight | BMI ≤40 | Ph 1 | Recruiting | 10 | Apr 2027 | - | |
| NCT07327281A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects | TQF3250 Prediabetes / glucose intolerance | BMI 20-40 | Ph 1 | Recruiting | 1 | Dec 2026 | - |
Showing 1-3 of 3 trials